Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.

Authors: Stephen J. Freedland, Ugo De Giorgi, Ronald F. Tutrone, Lawrence Ivan Karsh, Miguel Ramirez-Backhaus, Edward M. Uchio, Yiyun Tang, Ruslan Croitoru, Matt Rosales, Matko Kalac, Fong Wang, Neal D. Shore

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.5103

Source: Full article


Abstract

5103